Clinical Potential of Nerve Input to Tumors: A Bioelectricity Perspective

Phillips, Jade A.; Hutchings, Charlotte; Djamgoz, M.B.A.

doi:10.1089/bioe.2020.0051

Cited by 5 publications

(4 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Optogenetics research can inspire the development of novel closed-loop neurostimulation systems [ 225 ]. By combining optogenetic techniques with responsive neurostimulation technologies, it may be possible to create closed-loop systems that detect aberrant neural activity and deliver precisely timed light stimulation to prevent or disrupt seizure activity [ 130 , 226 ]. This hybrid approach could potentially offer a personalized and adaptive therapy for individuals with drug-resistant epilepsy.…”

Section: Optogenetics In Epilepsy Researchmentioning

confidence: 99%

A Comprehensive Review of Emerging Trends and Innovative Therapies in Epilepsy Management

Ghosh,

Sinha,

Ghosh

et al. 2023

Brain Sciences

View full text Add to dashboard Cite

Epilepsy is a complex neurological disorder affecting millions worldwide, with a substantial number of patients facing drug-resistant epilepsy. This comprehensive review explores innovative therapies for epilepsy management, focusing on their principles, clinical evidence, and potential applications. Traditional antiseizure medications (ASMs) form the cornerstone of epilepsy treatment, but their limitations necessitate alternative approaches. The review delves into cutting-edge therapies such as responsive neurostimulation (RNS), vagus nerve stimulation (VNS), and deep brain stimulation (DBS), highlighting their mechanisms of action and promising clinical outcomes. Additionally, the potential of gene therapies and optogenetics in epilepsy research is discussed, revealing groundbreaking findings that shed light on seizure mechanisms. Insights into cannabidiol (CBD) and the ketogenic diet as adjunctive therapies further broaden the spectrum of epilepsy management. Challenges in achieving seizure control with traditional therapies, including treatment resistance and individual variability, are addressed. The importance of staying updated with emerging trends in epilepsy management is emphasized, along with the hope for improved therapeutic options. Future research directions, such as combining therapies, AI applications, and non-invasive optogenetics, hold promise for personalized and effective epilepsy treatment. As the field advances, collaboration among researchers of natural and synthetic biochemistry, clinicians from different streams and various forms of medicine, and patients will drive progress toward better seizure control and a higher quality of life for individuals living with epilepsy.

show abstract

Section: Optogenetics In Epilepsy Researchmentioning

confidence: 99%

A Comprehensive Review of Emerging Trends and Innovative Therapies in Epilepsy Management

Ghosh,

Sinha,

Ghosh

et al. 2023

Brain Sciences

View full text Add to dashboard Cite

show abstract

“…In chemogenetics, genetically modified cells are engineered to express designer receptors exclusively activated by designer drugs (DREADDs). For example, neurons with mutant G-protein-coupled muscarinic acetylcholine receptors respond to the synthetic drug clozapine-N-oxide (CNO) instead of acetylcholine [ 114 , 115 , 116 ]. A G q -coupled DREADD (hM3Dq) can be used to enhance neuronal activity, whereas another G i/o -coupled DREADD (hM4Di) may inhibit neuronal activity [ 116 ].…”

Section: Review Of the Literaturementioning

confidence: 99%

“…In this line, CNO, an already accepted and administered compound with no significant side effects in humans, could be used to control cancer. For the application of chemogenetics in human cancer, the selection of the desired neuronal groups (e.g., those involved in stress response) or cancer cells (that are to be directly targeted), genetic manipulation of the exact receptor and ligand combinations, and definition of the proper timing will all be essential [ 114 , 115 ]. While in a very early stage of development, this receptor-specific approach has a great potential for future implementation in precision oncology.…”

Section: Review Of the Literaturementioning

confidence: 99%

ß-Adrenoreceptors in Human Cancers

Kraboth

Kálmán

2023

IJMS

View full text Add to dashboard Cite

Cancer is the leading cause of death and represents a significant economic burden worldwide. The numbers are constantly growing as a result of increasing life expectancy, toxic environmental factors, and adoption of Western lifestyle. Among lifestyle factors, stress and the related signaling pathways have recently been implicated in the development of tumors. Here we present some epidemiological and preclinical data concerning stress-related activation of the ß-adrenoreceptors (ß-ARs), which contributes to the formation, sequential transformation, and migration of different tumor cell types. We focused our survey on research results for breast and lung cancer, melanoma, and gliomas published in the past five years. Based on the converging evidence, we present a conceptual framework of how cancer cells hijack a physiological mechanism involving ß-ARs toward a positive modulation of their own survival. In addition, we also highlight the potential contribution of ß-AR activation to tumorigenesis and metastasis formation. Finally, we outline the antitumor effects of targeting the ß-adrenergic signaling pathways, methods for which primarily include repurposed ß-blocker drugs. However, we also call attention to the emerging (though as yet largely explorative) method of chemogenetics, which has a great potential in suppressing tumor growth either by selectively modulating neuronal cell groups involved in stress responses affecting cancer cells or by directly manipulating specific (e.g., the ß-AR) receptors on a tumor and its microenvironment.

show abstract

“…Not only is it crucial to characterize the cancer cells themselves, but also the tumor microenvironment (TME). The TME includes the non-tumor cells, extracellular matrix, and local microbiota [2], as well as the biochemical, biophysical [3], and bioelectric conditions of the stroma and interstitial fluid that exist in and around a tumor [4,5]. Our basic understanding of the PDAC TME is rapidly evolving, and a combination of experimental and observational evidence indicates that the TME affects clinical outcomes in PDAC by influencing its outgrowth and responses to therapy [6,7].…”

Section: Introductionmentioning

confidence: 99%

Clinical Evaluation of the Pancreatic Cancer Microenvironment: Opportunities and Challenges

Szczepanski,

Rudolf,

Shi

2024

Cancers

View full text Add to dashboard Cite

Advances in our understanding of pancreatic ductal adenocarcinoma (PDAC) and its tumor microenvironment (TME) have the potential to transform treatment for the hundreds of thousands of patients who are diagnosed each year. Whereas the clinical assessment of cancer cell genetics has grown increasingly sophisticated and personalized, current protocols to evaluate the TME have lagged, despite evidence that the TME can be heterogeneous within and between patients. Here, we outline current protocols for PDAC diagnosis and management, review novel biomarkers, and highlight potential opportunities and challenges when evaluating the PDAC TME as we prepare to translate emerging TME-directed therapies to the clinic.

show abstract

Clinical Potential of Nerve Input to Tumors: A Bioelectricity Perspective

Cited by 5 publications

References 127 publications

A Comprehensive Review of Emerging Trends and Innovative Therapies in Epilepsy Management

A Comprehensive Review of Emerging Trends and Innovative Therapies in Epilepsy Management

ß-Adrenoreceptors in Human Cancers

Clinical Evaluation of the Pancreatic Cancer Microenvironment: Opportunities and Challenges

Contact Info

Product

Resources

About